Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 3/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.47 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985944 | 0.87 | LRRK2 (0.52) | MAPK7LRRK2BRD4BRDTDCLK1 | |
| SCHEMBL18018900 | 0.86 | MAPK7 (0.55) | MAPK7LRRK2BRD4BRDTDCLK1 | |
| SCHEMBL18018798 | 0.86 | TTK (0.54) | MAPK7LRRK2BRD4BRDTDCLK1 | |
| SCHEMBL18018898 | 0.83 | MAPK7 (0.48) | MAPK7LRRK2BRD4BRDTDCLK1 | |
| SCHEMBL18018896 | 0.77 | ALK (0.53) | MAPK7LRRK2BRD4BRDTDCLK1 | |
| SCHEMBL18018889 | 0.76 | ALK (0.60) | MAPK7LRRK2BRD4BRDTDCLK1 | |
| SCHEMBL3706137 | 0.75 | LRRK2 (0.49) | MAPK7LRRK2TTK | |
| SCHEMBL22985860 | 0.73 | LRRK2 (0.53) | MAPK7LRRK2BRD4BRDTDCLK1 | |
| SCHEMBL4047900 | 0.73 | FES (0.66) | MAPK7LRRK2DCLK1DYRK1ATTK | |
| SCHEMBL22985881 | 0.72 | MAPK7 (0.53) | MAPK7LRRK2BRD4BRDTDCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |